Skip to content

Early Smoking Reduction or Cessation by Means of no Nicotine Electronic Cigarette Added to Standard Counselling.

Evaluation of Early Smoking Reduction or Cessation by Means of no Nicotine Electronic Cigarette Added to Standard Counselling.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01733706
Enrollment
75
Registered
2012-11-27
Start date
2011-06-30
Completion date
2015-12-31
Last updated
2017-02-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer, Myocardial Infarction

Keywords

No Nicotine Electronic Cigarette, Antismoke intervention

Brief summary

The aim of this study is the evaluation of early smoking reduction or cessation by means of no nicotine electronic cigarette added to standard counselling.

Detailed description

Cigarette smoking is one of the major health problems in the modern world for the impact on morbidity and mortality with devastating effects on cardio-cerebrovascular system and on tumor onset. After years of scientific doubts, today the scientific world agrees to define cigarette smoking not a vice but a disease. The aim is to evaluate the effect of no nicotine electronic cigarette use in patients with cancer or myocardial infarction, smoking at least 10 cigarettes per day for at least 10 years, in addition to counselling activity performed by specialised dedicated medical doctors. If patient is eligible for this trial, he will be enrolled in this trial and randomized. Randomization will be performed using a web-based procedure. Study participants will be randomized to electronic cigarette added to standard counselling or only standard counselling. A calendar will be given to the patient to remember the dates of visits or telephone counselling. After the first visit patient will be followed every ten days for the first two month through outpatient clinic visits and telephone counselling. After the first two months patient will return at institute for a last outpatient clinic visit at sixth month.

Interventions

DEVICENo nicotine electronic cigarette

The e-cigarette T-FUMOTM is a no nicotine electronic cigarette specifically designed to inactivate the early effects of the cessation of cigarette smoking, such as the craving caused by psychological reasons. It's formed by a filter which contains distilled water and food flavorings, an atomizer and a battery. On the opposite end to the filter there is a diode that lights up during aspiration. During the suction is generated hot air which, in contact with the liquid of the filter, generates steam which simulates the smoke of a traditional cigarette. The smoker has the sensation of smoking, but he does not suck the carcinogenic substances in traditional cigarettes and he does not assimilate nicotine.

standard counseling

Sponsors

European Institute of Oncology
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* patients with a diagnosis of cancer and recently operated at European Institute of Oncology at Milan (Italy); * patients with a diagnosis of hematology cancer treated at Foundation San Raffaele del Monte Tabor at Milan; * patient with a recent occurrence of acute myocardial infarction from Monzino Cardiology Centre at Milan; * age greater than 18 years; * smokers stable for at least 10 cigarettes per day for at least 10 years.

Exclusion criteria

* patients with life expectancy less than 6 months; * patients who have undertaken structured attempts to stop smoking over the past 3 months.

Design outcomes

Primary

MeasureTime frameDescription
Number of cigarettes smokedtwo months after event (cancer or myocardial infarction)
psychological conditionstwo months after event (cancer or myocardial infarction)psychological conditions will be assessed by questionnaire

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026